Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2008

Open Access 01-12-2008 | Original investigation

Interaction between Calpain 5, Peroxisome proliferator-activated receptor-gamma and Peroxisome proliferator-activated receptor-delta genes: a polygenic approach to obesity

Authors: María E Sáez, Antonio Grilo, Francisco J Morón, Luis Manzano, María T Martínez-Larrad, Antonio González-Pérez, Javier Serrano-Hernando, Agustín Ruiz, Reposo Ramírez-Lorca, Manuel Serrano-Ríos

Published in: Cardiovascular Diabetology | Issue 1/2008

Login to get access

Abstract

Context

Obesity is a multifactorial disorder, that is, a disease determined by the combined effect of genes and environment. In this context, polygenic approaches are needed.

Objective

To investigate the possibility of the existence of a crosstalk between the CALPAIN 10 homologue CALPAIN 5 and nuclear receptors of the peroxisome proliferator-activated receptors family.

Design

Cross-sectional, genetic association study and gene-gene interaction analysis.

Subjects

The study sample comprise 1953 individuals, 725 obese (defined as body mass index ≥ 30) and 1228 non obese subjects.

Results

In the monogenic analysis, only the peroxisome proliferator-activated receptor delta (PPARD) gene was associated with obesity (OR = 1.43 [1.04–1.97], p = 0.027). In addition, we have found a significant interaction between CAPN5 and PPARD genes (p = 0.038) that reduces the risk for obesity in a 55%.

Conclusion

Our results suggest that CAPN5 and PPARD gene products may also interact in vivo.
Appendix
Available only for authorised users
Literature
1.
Bell CG, Walley AJ, Froguel P: The genetics of human obesity. Nature reviews. 2005, 6 (3): 221-234.CrossRefPubMed
2.
Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Perusse L, Bouchard C: The human obesity gene map: the 2005 update. Obesity (Silver Spring, Md. 2006, 14 (4): 529-644.CrossRef
3.
Korner A, Kiess W, Stumvoll M, Kovacs P: Polygenic contribution to obesity: genome-wide strategies reveal new targets. Frontiers of hormone research. 2008, 36: 12-36.PubMed
4.
Romao I, Roth J: Genetic and environmental interactions in obesity and type 2 diabetes. Journal of the American Dietetic Association. 2008, 108 (4 Suppl 1): S24-8. 10.1016/j.jada.2008.01.022.CrossRefPubMed
5.
Gulick T, Cresci S, Caira T, Moore DD, Kelly DP: The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proceedings of the National Academy of Sciences of the United States of America. 1994, 91 (23): 11012-11016. 10.1073/pnas.91.23.11012.PubMedCentralCrossRefPubMed
6.
Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM: mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes & development. 1994, 8 (10): 1224-1234. 10.1101/gad.8.10.1224.CrossRef
7.
He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM: Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proceedings of the National Academy of Sciences of the United States of America. 2003, 100 (26): 15712-15717. 10.1073/pnas.2536828100.PubMedCentralCrossRefPubMed
8.
Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J: Muscle-specific Pparg deletion causes insulin resistance. Nature medicine. 2003, 9 (12): 1491-1497. 10.1038/nm956.CrossRefPubMed
9.
Shulman AI, Mangelsdorf DJ: Retinoid x receptor heterodimers in the metabolic syndrome. The New England journal of medicine. 2005, 353 (6): 604-615. 10.1056/NEJMra043590.CrossRefPubMed
10.
Tonjes A, Scholz M, Loeffler M, Stumvoll M: Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes care. 2006, 29 (11): 2489-2497. 10.2337/dc06-0513.CrossRefPubMed
11.
Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM: Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell. 2003, 113 (2): 159-170. 10.1016/S0092-8674(03)00269-1.CrossRefPubMed
12.
Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J: Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2003, 100 (26): 15924-15929. 10.1073/pnas.0306981100.PubMedCentralCrossRefPubMed
13.
Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, Cullinan CA, Sparrow CP, Baffic J, Berger GD, Santini C, Marquis RW, Tolman RL, Smith RG, Moller DE, Auwerx J: Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS letters. 2000, 473 (3): 333-336. 10.1016/S0014-5793(00)01554-4.CrossRefPubMed
14.
Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM: A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Sciences of the United States of America. 2001, 98 (9): 5306-5311. 10.1073/pnas.091021198.PubMedCentralCrossRefPubMed
15.
Shin HD, Park BL, Kim LH, Jung HS, Cho YM, Moon MK, Park YJ, Lee HK, Park KS: Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity. Diabetes. 2004, 53 (3): 847-851. 10.2337/diabetes.53.3.847.CrossRefPubMed
16.
Aberle J, Hopfer I, Beil FU, Seedorf U: Association of peroxisome proliferator-activated receptor delta +294T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V. Int J Obes (Lond). 2006, 30 (12): 1709-1713. 10.1038/sj.ijo.0803345.CrossRef
17.
Aberle J, Hopfer I, Beil FU, Seedorf U: Association of the T+294C polymorphism in PPAR delta with low HDL cholesterol and coronary heart disease risk in women. International journal of medical sciences. 2006, 3 (3): 108-111.PubMedCentralCrossRefPubMed
18.
Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W: The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls. Atherosclerosis. 2005, 183 (2): 336-341. 10.1016/j.atherosclerosis.2005.03.016.CrossRefPubMed
19.
Robitaille J, Gaudet D, Perusse L, Vohl MC: Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta -87T>C polymorphism and dietary fat in French-Canadians. Int J Obes (Lond). 2007, 31 (3): 411-417. 10.1038/sj.ijo.0803450.CrossRef
20.
Grarup N, Albrechtsen A, Ek J, Borch-Johnsen K, Jorgensen T, Schmitz O, Hansen T, Pedersen O: Variation in the peroxisome proliferator-activated receptor delta gene in relation to common metabolic traits in 7,495 middle-aged white people. Diabetologia. 2007, 50 (6): 1201-1208. 10.1007/s00125-007-0668-2.CrossRefPubMed
21.
Lagou V, Scott RA, Manios Y, Chen TL, Wang G, Grammatikaki E, Kortsalioudaki C, Liarigkovinos T, Moschonis G, Roma-Giannikou E, Pitsiladis YP: Impact of peroxisome proliferator-activated receptors gamma and delta on adiposity in toddlers and preschoolers in the GENESIS Study. Obesity (Silver Spring, Md. 2008, 16 (4): 913-918.CrossRef
22.
Hautala AJ, Leon AS, Skinner JS, Rao DC, Bouchard C, Rankinen T: Peroxisome proliferator-activated receptor-delta polymorphisms are associated with physical performance and plasma lipids: the HERITAGE Family Study. American journal of physiology. 2007, 292 (5): H2498-505.PubMed
23.
Stefan N, Thamer C, Staiger H, Machicao F, Machann J, Schick F, Venter C, Niess A, Laakso M, Fritsche A, Haring HU: Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. The Journal of clinical endocrinology and metabolism. 2007, 92 (5): 1827-1833. 10.1210/jc.2006-1785.CrossRefPubMed
24.
Saez ME, Ramirez-Lorca R, Moron FJ, Ruiz A: The therapeutic potential of the calpain family: new aspects. Drug Discov Today. 2006, 11 (19-20): 917-923. 10.1016/j.drudis.2006.08.009.CrossRefPubMed
25.
Gao G, Dou QP: N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome C release and apoptotic cell death. Journal of cellular biochemistry. 2000, 80 (1): 53-72. 10.1002/1097-4644(20010101)80:1<53::AID-JCB60>3.0.CO;2-E.CrossRefPubMed
26.
Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, Hinokio Y, Lindner TH, Mashima H, Schwarz PE, del Bosque-Plata L, Horikawa Y, Oda Y, Yoshiuchi I, Colilla S, Polonsky KS, Wei S, Concannon P, Iwasaki N, Schulze J, Baier LJ, Bogardus C, Groop L, Boerwinkle E, Hanis CL, Bell GI: Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nature genetics. 2000, 26 (2): 163-175. 10.1038/79876.CrossRefPubMed
27.
Johnson JD, Han Z, Otani K, Ye H, Zhang Y, Wu H, Horikawa Y, Misler S, Bell GI, Polonsky KS: RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets. The Journal of biological chemistry. 2004, 279 (23): 24794-24802. 10.1074/jbc.M401216200.CrossRefPubMed
28.
Arrington DD, Van Vleet TR, Schnellmann RG: Calpain 10: a mitochondrial calpain and its role in calcium-induced mitochondrial dysfunction. Am J Physiol Cell Physiol. 2006, 291 (6): C1159-71. 10.1152/ajpcell.00207.2006.CrossRefPubMed
29.
Gonzalez A, Saez ME, Aragon MJ, Galan JJ, Vettori P, Molina L, Rubio C, Real LM, Ruiz A, Ramirez-Lorca R: Specific haplotypes of the CALPAIN-5 gene are associated with polycystic ovary syndrome. Human reproduction (Oxford, England). 2006, 21 (4): 943-951. 10.1093/humrep/dei443.CrossRef
30.
Saez ME, Martinez-Larrad MT, Ramirez-Lorca R, Gonzalez-Sanchez JL, Zabena C, Martinez-Calatrava MJ, Gonzalez A, Moron FJ, Ruiz A, Serrano-Rios M: Calpain-5 gene variants are associated with diastolic blood pressure and cholesterol levels. BMC medical genetics. 2007, 8: 1-10.1186/1471-2350-8-1.PubMedCentralCrossRefPubMed
31.
Casas F, Daury L, Grandemange S, Busson M, Seyer P, Hatier R, Carazo A, Cabello G, Wrutniak-Cabello C: Endocrine regulation of mitochondrial activity: involvement of truncated RXRalpha and c-Erb Aalpha1 proteins. Faseb J. 2003, 17 (3): 426-436. 10.1096/fj.02-0732com.CrossRefPubMed
32.
Matsushima-Nishiwaki R, Shidoji Y, Nishiwaki S, Moriwaki H, Muto Y: Limited degradation of retinoid X receptor by calpain. Biochemical and biophysical research communications. 1996, 225 (3): 946-951. 10.1006/bbrc.1996.1276.CrossRefPubMed
33.
Yajima Y, Sato M, Sorimachi H, Inomata M, Maki M, Kawashima S: Calpain system regulates the differentiation of adult primitive mesenchymal ST-13 adipocytes. Endocrinology. 2006, 147 (10): 4811-4819. 10.1210/en.2005-1647.CrossRefPubMed
34.
Hodgkinson CP, Ye S: Microarray analysis of peroxisome proliferator-activated receptor-gamma induced changes in gene expression in macrophages. Biochemical and biophysical research communications. 2003, 308 (3): 505-510. 10.1016/S0006-291X(03)01416-5.CrossRefPubMed
35.
Martinez-Larrad MT, Fernandez-Perez C, Gonzalez-Sanchez JL, Lopez A, Fernandez-Alvarez J, Riviriego J, Serrano-Rios M: [Prevalence of the metabolic syndrome (ATP-III criteria). Population-based study of rural and urban areas in the Spanish province of Segovia]. Medicina clinica. 2005, 125 (13): 481-486. 10.1157/13080210.CrossRefPubMed
36.
Ramirez-Lorca R, Grilo A, Martinez-Larrad MT, Manzano L, Serrano-Hernando FJ, Moron FJ, Perez-Gonzalez V, Gonzalez-Sanchez JL, Fresneda J, Fernandez-Parrilla R, Monux G, Molero E, Sanchez E, Martinez-Calatrava MJ, Saban-Ruiz J, Ruiz A, Saez ME, Serrano-Rios M: Sex and body mass index specific regulation of blood pressure by CYP19A1 gene variants. Hypertension. 2007, 50 (5): 884-890. 10.1161/HYPERTENSIONAHA.107.096263.CrossRefPubMed
37.
Ronaghi M, Karamohamed S, Pettersson B, Uhlen M, Nyren P: Real-time DNA sequencing using detection of pyrophosphate release. Analytical biochemistry. 1996, 242 (1): 84-89. 10.1006/abio.1996.0432.CrossRefPubMed
38.
Sasieni PD: From genotypes to genes: doubling the sample size. Biometrics. 1997, 53 (4): 1253-1261. 10.2307/2533494.CrossRefPubMed
39.
Gonzalez Sanchez JL, Serrano Rios M, Fernandez Perez C, Laakso M, Martinez Larrad MT: Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. European journal of endocrinology / European Federation of Endocrine Societies. 2002, 147 (4): 495-501.CrossRefPubMed
40.
Ochoa MC, Marti A, Azcona C, Chueca M, Oyarzabal M, Pelach R, Patino A, Moreno-Aliaga MJ, Martinez-Gonzalez MA, Martinez JA: Gene-gene interaction between PPAR gamma 2 and ADR beta 3 increases obesity risk in children and adolescents. Int J Obes Relat Metab Disord. 2004, 28 Suppl 3: S37-41. 10.1038/sj.ijo.0802803.CrossRefPubMed
41.
Soriguer F, Morcillo S, Cardona F, Rojo-Martinez G, de la Cruz Almaraz M, Ruiz de Adana Mde L, Olveira G, Tinahones F, Esteva I: Pro12Ala polymorphism of the PPARG2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. The Journal of nutrition. 2006, 136 (9): 2325-2330.PubMed
42.
Giguere CJ, Covington MD, Schnellmann RG: Mitochondrial calpain 10 activity and expression in the kidney of multiple species. Biochemical and biophysical research communications. 2007, 366 (1): 258-262. 10.1016/j.bbrc.2007.11.133.PubMedCentralCrossRefPubMed
43.
Lee J, Sharma S, Kim J, Ferrante RJ, Ryu H: Mitochondrial nuclear receptors and transcription factors: Who's minding the cell?. Journal of neuroscience research. 2007
44.
Randriamboavonjy V, Pistrosch F, Bolck B, Schwinger RH, Dixit M, Badenhoop K, Cohen RA, Busse R, Fleming I: Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and {micro}-Calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation. 2007
45.
Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, Ellerby LM: Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. The Journal of biological chemistry. 2004, 279 (19): 20211-20220. 10.1074/jbc.M401267200.CrossRefPubMed
46.
Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M: Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer research. 2007, 67 (19): 9001-9005. 10.1158/0008-5472.CAN-07-1072.CrossRefPubMed
47.
Pelley RP, Chinnakannu K, Murthy S, Strickland FM, Menon M, Dou QP, Barrack ER, Reddy GP: Calmodulin-androgen receptor (AR) interaction: calcium-dependent, calpain-mediated breakdown of AR in LNCaP prostate cancer cells. Cancer research. 2006, 66 (24): 11754-11762. 10.1158/0008-5472.CAN-06-2918.CrossRefPubMed
48.
Murayama A, Fukai F, Murachi T: Action of calpain on the basic estrogen receptor molecule of porcine uterus. Journal of biochemistry. 1984, 95 (6): 1697-1704.PubMed
49.
Shiba E, Kim S, Fujitani M, Kambayashi JI, Kawamura I, Tsujimoto S, Shimomura K, Tanji Y, Taguchi T, Kimoto Y, Izukura M, Takai SI: Possible involvement of calpain in the growth of estrogen receptor positive breast cancer cells. Anticancer research. 1996, 16 (2): 773-777.PubMed
50.
Nishikiori N, Osanai M, Chiba H, Kojima T, Ohguro H, Sawada N: Inhibitory effects of retinoic acid receptor alpha stimulants on murine cataractogenesis through suppression of deregulated calpains. Investigative ophthalmology & visual science. 2007, 48 (5): 2224-2229. 10.1167/iovs.06-1222.CrossRef
51.
Sribnick EA, Matzelle DD, Ray SK, Banik NL: Estrogen treatment of spinal cord injury attenuates calpain activation and apoptosis. Journal of neuroscience research. 2006, 84 (5): 1064-1075. 10.1002/jnr.21016.CrossRefPubMed
52.
Gamerdinger M, Manthey D, Behl C: Oestrogen receptor subtype-specific repression of calpain expression and calpain enzymatic activity in neuronal cells--implications for neuroprotection against Ca-mediated excitotoxicity. Journal of neurochemistry. 2006, 97 (1): 57-68. 10.1111/j.1471-4159.2006.03675.x.CrossRefPubMed
53.
Aranceta J, Perez Rodrigo C, Serra Majem L, Ribas Barba L, Quiles Izquierdo J, Vioque J, Tur Mari J, Mataix Verdu J, Llopis Gonzalez J, Tojo R, Foz Sala M: [Prevalence of obesity in Spain: results of the SEEDO 2000 study]. Medicina clinica. 2003, 120 (16): 608-612. 10.1157/13046926.CrossRefPubMed
54.
Reichrath J, Rech M, Seifert M: Vitamin D-induced apoptosis and melanoma: does calpain represent the major execution protease rather than caspases?. The Journal of pathology. 2003, 201 (2): 335-336. 10.1002/path.1445.CrossRefPubMed
Metadata
Title
Interaction between Calpain 5, Peroxisome proliferator-activated receptor-gamma and Peroxisome proliferator-activated receptor-delta genes: a polygenic approach to obesity
Authors
María E Sáez
Antonio Grilo
Francisco J Morón
Luis Manzano
María T Martínez-Larrad
Antonio González-Pérez
Javier Serrano-Hernando
Agustín Ruiz
Reposo Ramírez-Lorca
Manuel Serrano-Ríos
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2008
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-7-23

Other articles of this Issue 1/2008

Cardiovascular Diabetology 1/2008 Go to the issue

Original investigation

Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity?

Original investigation

Association between intrarenal arterial resistance and diastolic dysfunction in type 2 diabetes

Hypothesis

Are the adverse effects of glitazones linked to induced testosterone deficiency?

Original investigation

Exercise training enhanced myocardial endothelial nitric oxide synthase (eNOS) function in diabetic Goto-Kakizaki (GK) rats

Original investigation

Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 Diabetes Mellitus

Original investigation

Exercise-induced expression of angiogenic growth factors in skeletal muscle and in capillaries of healthy and diabetic mice
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits